Research on the weight loss drug CagriSema by Noor and Noord

GoldenOctober2024

2025-02-05 11:34:47

On February 5th, Jinshi Data reported that Novo Nordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. In December of last year, the data of the drug disappointed the market, causing the company’s stock price to fall by 27%, which was one of the largest single-day declines for a European company. The CEO, Jorgensen, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they see in the data.

View Original

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.

Comment

0/400

No comments